BTL Group Challenges WonderFace Device with Patent Infringement Lawsuit

BTL Group Takes Legal Action Against WonderFace Device

Date: October 8, 2025
Location: Prague, Czech Republic

In a significant move for the medical technology sector, BTL Group, a renowned global provider of medical solutions, has filed a patent infringement lawsuit against Lexter Microelectronic Engineering Systems S.L., the company behind the WonderFace device. This international action was initiated at the Unified Patent Court, underscoring BTL’s commitment to protecting its innovative technologies from what it perceives as infringement.

The heart of the lawsuit centers around BTL’s patents related to its pioneering EMFACE® technology. This revolutionary advancement in facial procedures combines targeted muscle stimulation with radiofrequency heating, utilizing unique hands-free applicators to deliver results that redefine beauty treatments. The company asserts that the WonderFace device violates the patents associated with EMFACE®, which has set a new standard in facial lifting procedures.

Tomas Schwarz, CEO of BTL, expressed the company’s unwavering stance on intellectual property rights: "We will vigorously defend our intellectual property to protect the investments of our clients. This lawsuit marks the beginning of our broader effort to take legal action against any third party that we believe infringes upon our innovations."

With this legal move, BTL aims to prohibit the distribution of WonderFace systems across numerous countries. A successful ruling in this case could have ramifications in 18 different jurisdictions, emphasizing the legal stakes and the expansive reach of BTL's enforcement strategy. This sequence of events reflects the intensifying competition in the medical aesthetics industry, particularly around innovative technologies aimed at enhancing cosmetic outcomes.

The EMFACE® technology, recognized for its efficiency and effectiveness, has been a cornerstone of BTL’s product line. Founded in 1993, BTL has propelled itself to the forefront of the medical device industry, boasting over 200 patents and a dedicated team of more than 600 in-house engineers focused on the advancement of medical treatments.

The ramifications of this lawsuit could reshape the landscape of facial aesthetic treatments and attrition in the market for technologies that aim to improve skin elasticity and muscle tone in the face. As the industry evolves, the importance of intellectual property rights continues to be paramount for safeguarding innovations that drive the medical aesthetics field forward.

BTL invites those interested in learning more about the EMFACE® technology to visit www.emface.com. This legal assertion not only protects their innovations but also showcases their dedication to providing exceptional solutions in dermatology, plastic surgery, and beyond.

As the situation develops, stakeholders in both the medical and consumer sectors will be observing closely, anticipating the outcomes and consequences of this high-stakes legal battle. By standing firm against perceived infringements, BTL is not only protecting its interests but also asserting its role as a leader in clinical technology that prioritizes patient care and treatment efficacy.